Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16022261 | 1.00 | CHEK1 (0.55) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL14514301 | 0.79 | CHEK1 (0.61) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL16525049 | 0.79 | CHEK1 (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL29927648 | 0.79 | CHEK1 (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL16022491 | 0.78 | CHEK1 (0.48) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL16525447 | 0.77 | CHEK1 (0.43) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL26131443 | 0.77 | CHEK1 (0.59) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL27661379 | 0.76 | CHEK1 (0.57) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL16025834 | 0.74 | CHEK1 (0.55) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3932235 | 0.73 | CHEK1 (0.53) | CHEK1AURKADAPK3CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-115697990-B | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025072629-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4121422-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CHEK1 133/4885AURKA 996/4885DAPK3 531/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | CHEK1 133/4885AURKA 996/4885DAPK3 531/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | CHEK1 328/4885AURKA 952/4885DAPK3 964/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CHEK1 133/4885AURKA 996/4885DAPK3 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.